Renalytix
plc
("Renalytix" or the
"Company")
Block Admission and "At The
Market" Sales Agreement
LONDON and SALT LAKE CITY - 21
May 2024 -
Renalytix
plc (NASDAQ: RNLX) (LSE: RENX)
entered into an at-the-market offering agreement
with H.C. Wainwright & Co., LLC (the "Agent") on 15 May 2024 pursuant to
which the Company may issue and sell from time to time, at its
option, the Company's American Depositary Shares (the "ADSs", such ADSs being the
"Programme ADSs"), each
representing two ordinary shares nominal value £0.0025 per share of
the Company (the "Ordinary
Shares"), through or to the Agent, as sales agent and/or
principal, for an aggregate offering price of up to $15 million
(the "ATM
Programme").
Any Ordinary Shares to be
represented by the Programme ADSs will be allotted and issued
pursuant to the resolutions adopted at the Company's general
meeting on 22 April 2024 and/or any replacement resolutions to
allot and issue Ordinary Shares adopted by the Company's
shareholders from time to time.
The sale, if any, of the Programme
ADSs will be made by any methods permitted that is deemed to be an
"at-the-market" equity offering as defined in Rule 415(a)(4)
promulgated under the U.S. Securities Act of 1933, as amended,
including sales made directly on The Nasdaq Global Market or any
other trading market for the Company's ADSs. The Programme
ADSs, if any, will be issued and sold pursuant to the Company's
registration statement on Form S-3 (File No. 333-274733), which
became effective on 6 October 2023 and the related prospectus
supplement dated 15 May 2024, in each case filed with the U.S.
Securities and Exchange Commission (the "SEC"). A copy of the registration
statement and the prospectus supplement may be obtained on the
SEC's website at www.sec.gov.
Block Admission Application
Application has been made to London
Stock Exchange plc for a block admission ("Block Admission") of up to 51,356,400
new Ordinary Shares which may be allotted and issued in connection
with the ATM Programme. It is expected that the Block Admission
will become effective on 22 May
2024.
The Block Admission, representing
approximately 33% of the current issued share capital, is being
made for the allotment and issue of new Ordinary Shares to be
represented by the Programme ADSs. Following the Block Admission,
the Company's issued share capital remains unchanged at 154,368,191
Ordinary Shares.
If and when issued, the new Ordinary
Shares to be represented by the Programme ADSs will rank
pari passu in all respects
with the existing Ordinary Shares in the Company.
The Company will announce any issue
of Ordinary Shares to be represented by the Programme ADSs from
time to time, together with the number of Ordinary Shares in issue
pursuant to Rule 2.9 of the City Code on Takeovers and
Mergers. Such number of issued Ordinary Shares may be used by
shareholders as the denominator for the calculation by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company
pursuant to the Disclosure Guidance and Transparency Rules of the
Financial Conduct Authority and the AIM Rules for Companies (the
"AIM Rules"). The Company
will also make six-monthly announcements regarding the utilisation
of the Block Admission in accordance with rule 29 of the AIM
Rules.
For further information,
please contact:
Renalytix plc
|
www.renalytix.com
|
James McCullough, CEO
|
Via Walbrook
PR
|
|
|
Stifel (Nominated Adviser, Joint Broker)
|
Tel: 020 7710
7600
|
Alex Price / Nicholas Moore / Nick
Harland / Samira Essebiyea
|
|
Harry Billen
|
|
Investec Bank plc (Joint Broker)
|
Tel: 020 7597
4000
|
Gary Clarence / Shalin
Bhamra
|
|
|
|
Walbrook PR Limited
Paul McManus / Alice Woodings /
Charlotte Edgar
|
Tel: 020 7933 8780 or
renalytix@walbrookpr.com
Mob: 07980 541 893 / 07407 804 654 /
07884 664 686
|
|
|
CapComm Partners
|
|
Peter DeNardo
|
Tel:
415-389-6400 or investors@renalytix.com
|
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX)
is an in-vitro diagnostics and laboratory services company that is
the global founder and leader in the new field of bioprognosis™ for
kidney health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit
www.renalytix.com.